Dasatinib - Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML), No Country

Onset of CML, showing that peak occurrence is in people aged 50-70 years. Incidence is slightly higher among males than females


«Back	\|	Next»